echemi logo
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Infection > [Cell Sub-Journal] Researchers successfully map the single-cell transcriptome of diffuse large B-cell lymphoma, which may help the treatment of patients with HBV-positive B-cell lymphoma

    [Cell Sub-Journal] Researchers successfully map the single-cell transcriptome of diffuse large B-cell lymphoma, which may help the treatment of patients with HBV-positive B-cell lymphoma

    • Last Update: 2022-06-13
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit

    This article was originally written by Translational Medicine.
    Please indicate the source Author: Sibyl Introduction: A collaborative research team from Sweden and China successfully mapped the single-cell transcriptome of diffuse large B-cell lymphoma (DLBCL), revealing DLBCL cases Phenotypic heterogeneity within and between cases, interactions between tumors and immune cells and other cells of the microenvironment, and features that affect tumor biology, such as hepatitis B virus (HBV) infection


    Co-corresponding author Qiang Pan-Hammarström, a researcher in life sciences and nutrition at the Karolinska Institute, said: "We discovered the developmental trajectory of malignant versus benign cells, the connection between malignant and tumor-infiltrating cells.
    interaction, we also found that the effects of chronic viral infection can further explain the disease heterogeneity in DLBCL


    In-depth studies of the somatic mutational spectrum and drug response of malignant cell subsets can provide additional insights into disease mechanisms and therapeutic strategies

    " The researchers performed droplet-based single-cell RNA-sequencing of more than 94,400 cells in 17 DLBCL patients, analyzing single-cell transcriptome data and whole-genome sequences, as well as bulk RNA-seq data

    They took tumor samples from three patients with Burkitt lymphoma, follicular lymphoma, and reactive lymph node hyperplasia, and compared the gene expression signatures in these samples with the data obtained

    The study, titled "A single-cell atlas of diffuse large B cell lymphoma," was published Tuesday (April 19) in the journal Cell Reports

    110713 "Using single-cell RNA-sequencing (scRNA-seq) technology, we created a comprehensive cellular map of malignant and benign cells in DLBCL, which also Allowing us to study the impact of chronic HBV infection on lymphoma at the single-cell level


    " In malignant DLBCL cells, the team found 73 distinct gene expression patterns, including eight that appeared in the reference sample

    Each sample contained 2 to 7 distinct gene expression patterns, providing clues to expression and signaling patterns of DLBCL treatment response, relapse, and outcome

    Meanwhile, in the tumor microenvironment, the researchers marked 8 clusters of B cells, 16 clusters of T cells and 6 clusters of spinal cord cells

    The researchers used the atlas of about 2,800 cell-to-cell interactions to predict and delve into the interactions between tumor cells and microenvironmental features

    They found that certain signals in the microenvironment appeared to increase tumor cell survival and identified a suppressor T-cell signature associated with T-cell immune exhaustion

    "Because B cells are also part of the immune system under normal conditions, compared with other solid tumors, the tumor microenvironment of B-cell lymphomas is characterized by the presence of malignant cells, infiltrating T cells and other immune cells," the researchers said.
    interactions are more complex


    " In a subset of HBV-infected samples, the team found changes in gene expression involving major histocompatibility complex (MHC) class II, interferon-gamma immune activity

    In these cases, although HBV-positive and negative DLBCL had similar non-malignant cellular components, other genes appeared to alter tumor interactions and outcomes

    "Taken together, the results suggest that HBV infection may have significant effects on both malignant and benign cells, and in general, the tumor microenvironment is more immunosuppressive in HBV-positive DLBCL patients," said the researchers

    Patients with HBV-positive DLBCL have a poor response to first-line immunochemotherapy, and our results may provide a molecular basis for clinical trials to give these patients alternative treatment options, such as combining anti-PD-1 or anti-CTLA with other immune checkpoint inhibitors Join together, treat together

    " Reference: https://#.
    Yl-nZoVByUk Note: This article is intended to introduce the progress of medical research and cannot be used as a reference for treatment plans


    For health guidance, please go to a regular hospital for treatment

    Recommendation·Activity Click on the text or scan the QR code to view the details.
    April 20th, 09:30-11:30 Online Scrap Cocoon-Super Multiple Immune Markers to Decipher the Mystery of Tumor Microenvironment :00 Online How to Improve the Efficiency of New Macromolecular Drug R&D from Basic Experiments Online Scanning Appointment Live April 21st 14:00-16:00 Online Deyun Kangrui Launched New RNA In Situ Sequencing Technology Scanning Appointment Live April 27th 19: 00-21:30 Online "Exploring Genes, Insights Against Epidemic" - Webinar on New Technologies for Pathogen Molecular Detection Scanning Scheduled Live April 28 10:00-11:30 Application of Online Protein Quantitative Evolution in the Field of Industrial Enzymes and Twist Bioscience's solution scanning appointment live broadcast April 28, 19:00-21:30 Online tumor precision diagnosis and treatment strategy progress and mass spectrometry research method scanning appointment live broadcast
    This article is an English version of an article which is originally in the Chinese language on and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to with relevant evidence.